Introduction Long-acting injectable depot buprenorphine is a recent addition to the suite of opioid agonist therapies (OAT) used to treat opioid use disorder (OUD). However, there has …
KB Malme, K Ulstein, AK Finbråten… - International Journal of …, 2023 - Elsevier
Background Improving HCV treatment uptake among people who inject drugs (PWID) is crucial to achieving the WHO elimination targets. The aims were to evaluate HCV treatment …
Highlights OAT treatment journeys in our sample were influenced by a broad range of individual, social and structural factors, with stigma presenting a pervasive barrier to …
Background: A large outbreak of HIV among people who inject drugs (PWID) has been ongoing in Glasgow city centre (GCC), Scotland since early 2015. The outbreak is …
F Mehrabi, S Mehmandoost, A Mirzazadeh… - International journal of …, 2024 - Springer
Injection drug use is the primary driver of the HIV epidemic in Iran. We characterized people who inject drugs (PWID) living in Iran who had never received opioid agonist therapy (OAT) …
EU Patel, SM Grieb, AK Winiker, J Ching… - Harm reduction …, 2024 - Springer
Background Substance use disorder treatment and recovery support services are critical for achieving and maintaining recovery. There are limited data on how structural and social …
I Sokale, J Wilkerson, P Wermuth, F Atem, J Burnett… - AIDS and Behavior, 2024 - Springer
Evaluating routine HIV testing and treatment and use of services for people who inject drugs (PWID) is critical to curb the ongoing HIV epidemic. We analyzed data from the 2018 …
Non-medical opioid use is a major public health concern causing high mortality. While opioid agonist maintenance treatment (OMT) is a key life-saving intervention, there is (a) no …
Background People who inject drugs (PWID) in Kenya have a high prevalence of HIV (14- 26%) and HCV (11-36%). Needle and syringe programmes (NSP) and antiretroviral therapy …